Search

Your search keyword '"Meagan P, O'Brien"' showing total 29 results

Search Constraints

Start Over You searched for: Author "Meagan P, O'Brien" Remove constraint Author: "Meagan P, O'Brien"
29 results on '"Meagan P, O'Brien"'

Search Results

1. Concordance between SARS-CoV-2 index individuals and their household contacts on index individual COVID-19 transmission cofactors: a comparison of self-reported and contact-reported information

2. Examining protective effects of SARS-CoV-2 neutralizing antibodies after vaccination or monoclonal antibody administration

3. Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19

4. Elevated serum IgA following vaccination against SARS-CoV-2 in a cohort of high-risk first responders

5. Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin interventionResearch in context

6. Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial

7. Platelet Transcriptome Profiling in HIV and ATP-Binding Cassette Subfamily C Member 4 (ABCC4) as a Mediator of Platelet Activity

8. Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in <scp>SARS CoV</scp> ‐2

9. A Prospective Study of Key Correlates for Household Transmission of SARS-CoV-2

10. Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double–Blind Trial

11. Pharmacokinetics and Concentration‐Response of Dupilumab in Patients With Seasonal Allergic Rhinitis

12. 1079. Casirivimab and Imdevimab (CAS + IMD) Antibody Combination for the Treatment of Immunocomprised Hospitalized Patients with COVID-19

13. Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders

14. Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial

15. REGN1908/1909 prevented cat allergen-induced early asthmatic responses in an environmental exposure unit

16. Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

17. Cat allergen exposure in a naturalistic exposure chamber: A prospective observational study in cat-allergic subjects

18. Repeat Subcutaneous Administration of REGEN-COV® in Adults is Well-Tolerated and Prevents the Occurrence of COVID-19

19. Subcutaneous REGEN-COV Antibody Combination for Covid-19 Prevention

20. Subcutaneous REGEN-COV Antibody Combination in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial

21. Monoclonal Antibody Treatment, Prophylaxis and Vaccines Combined to Reduce SARS CoV-2 Spread

22. A Randomized Placebo-Controlled Trial of Sarilumab in Hospitalized Patients with Covid-19

23. COVID-19 prevention with subcutaneous administration of the monoclonal antibodies casirivimab and imdevimab: Subgroup analysis in participants with cardiovascular disease and diabetes

24. Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study

25. P207 REPRODUCIBILITY OF THE EARLY ASTHMATIC RESPONSE AMONG CAT-ALLERGIC MILD ASTHMATICS IN A NATURALISTIC EXPOSURE CHAMBER

27. A Single-Dose of REGN1908-1909 Reduced Bronchoconstriction in Cat-Allergic Subjects with Mild Asthma for up to 3 months following a controlled cat allergen challenge: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

28. P052 ANTI-BET V_1 MAB COCKTAIL REDUCED BIRCH ALLERGIC SYMPTOMS WITHIN ONE WEEK, SUSTAINED OVER TWO MONTHS

29. P051 ANTI-BET V_1 MABS REDUCED BASOPHIL RESPONSIVENESS TO BIRCH POLLEN STIMULATION EX-VIVO IN BIRCH ALLERGIC PATIENTS

Catalog

Books, media, physical & digital resources